Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK. Bobbili PJ, et al. Among authors: oh wk. Clin Genitourin Cancer. 2024 Mar 23;22(3):102080. doi: 10.1016/j.clgc.2024.102080. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38653037 Free article.
Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.
Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. Oh WK, et al. Clin Genitourin Cancer. 2017 Jun 19:S1558-7673(17)30170-2. doi: 10.1016/j.clgc.2017.06.004. Online ahead of print. Clin Genitourin Cancer. 2017. PMID: 28729067
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP. Oh WK, et al. Urol Oncol. 2018 Nov;36(11):500.e1-500.e9. doi: 10.1016/j.urolonc.2018.08.002. Epub 2018 Sep 7. Urol Oncol. 2018. PMID: 30201382 Free article.
Accelerating precision medicine in metastatic prostate cancer.
Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H. Mateo J, et al. Nat Cancer. 2020 Nov;1(11):1041-1053. doi: 10.1038/s43018-020-00141-0. Epub 2020 Nov 17. Nat Cancer. 2020. PMID: 34258585 Free PMC article.
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Choueiri TK, et al. Among authors: oh wk. BJU Int. 2010 May;105(9):1247-54. doi: 10.1111/j.1464-410X.2009.08972.x. Epub 2009 Oct 26. BJU Int. 2010. PMID: 19863525
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. Oh WK, et al. Int J Oncol. 2014 Jan;44(1):5-16. doi: 10.3892/ijo.2013.2181. Epub 2013 Nov 15. Int J Oncol. 2014. PMID: 24247547 Free PMC article.
527 results